Carregant...
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared betwe...
Guardat en:
| Publicat a: | Diabetes Obes Metab |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Publishing Ltd
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5947308/ https://ncbi.nlm.nih.gov/pubmed/29316197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13211 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|